头颈癌检测残留病灶与预测复发的新兴近端液体活检方法:综述及新型液体分期建议
本综述探讨液体活检用于头颈鳞状细胞癌术后微小残留病灶监测与复发检测的潜力。提出整合唾液、手术引流淋巴液和外周血生物标志物的新型液体TNM(LiTNM)分期系统。近端液体活检(唾液和手术引流淋巴液)因靠近肿瘤微环境具优势,唾液在HPV相关口咽癌中显示高敏感性,手术引流淋巴液在识别早期术后复发方面有潜力,但标准化和验证仍是挑战。
要点
- 唾液在HPV相关口咽癌中检测具高敏感性。
- 手术引流淋巴液有助识别早期术后复发。
- 提出LiTNM分期系统整合唾液、引流液和外周血标志物。
核心结论
- 液体活检方法在术后疾病监测方面有前景,但临床实施仍处于早期阶段。
- 提出的LiTNM分期系统可通过提供分子风险分层框架来补充TNM分期。
- 需要严谨的前瞻性研究验证其临床效用并促进采用。
研究设计与样本
- 本综述探讨液体活检用于微小残留病灶和复发检测的潜力。
- 引入新型液体TNM(LiTNM)分期系统,整合唾液、手术引流淋巴液和外周血中的生物标志物。
主要发现
- 近端液体活检,特别是唾液和手术引流淋巴液,因靠近肿瘤微环境而具优势。
- 唾液在HPV相关口咽癌中显示高敏感性。
- 手术引流淋巴液在识别早期术后复发方面有潜力。
- 标准化和验证仍是挑战。
临床怎么用
- 原文未据此给出推荐。
局限性
- 标准化和验证仍是挑战。
- 临床实施仍处于早期阶段。
- 需要严谨的前瞻性研究验证LiTNM分期系统的临床效用并促进采用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Head and neck squamous cell carcinoma remains challenging due to high recurrence rates and poor survival outcomes. Developing precise technologies for disease burden assessment, treatment response, and minimal residual disease (MRD) surveillance is crucial for improving prognosis. METHODS: This review explores the potential of liquid biopsy for MRD and recurrence detection. A novel liquid TNM (LiTNM) staging system is introduced, integrating biomarkers from saliva, surgical drain lymphatic fluid (SLF), and peripheral blood. RESULTS: Proximal liquid biopsies, particularly saliva and SLF, offer advantages due to their proximity to the tumor microenvironment. Saliva demonstrates high sensitivity in HPV-associated oropharyngeal cancers, while SLF holds potential in identifying early postoperative recurrence. Despite these advancements, standardization and validation remain challenges. CONCLUSIONS: Liquid biopsy approaches show promise for postoperative disease monitoring, yet their clinical implementation remains in the early stages. The proposed LiTNM staging system could complement TNM staging by providing a molecular framework for risk stratification. However, rigorous prospective studies are necessary to validate its clinical utility and facilitate adoption.
引用
- Helou V, Smith JD, Harris M, et al. Emerging Proximal Liquid Biopsy Approaches for Detecting Residual Disease and Predicting Recurrence in Head and Neck Cancer: A Review and Proposal of Novel Liquid Staging. Head Neck. 2025. PMID: 40114519. doi:10.1002/hed.28138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。